Navigation Links
Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer

LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, presented today findings from its novel human-in-mouse (HIM) tissue transgenic cancer model system, in which AVEO successfully created invasive human tumors that develop over time in mice from primary human breast tissue. This model enables scientists, for the first time, to generate and study in vivo, human tumor initiation, progression and treatment in a preclinical model. This groundbreaking model was presented today in a session entitled "Mouse Models of Cancer 6: Signaling Mechanisms in Initiation, Progression and Therapeutics" at the 100th American Association for Cancer Research (AACR) Annual Meeting in Los Angeles, California.

"For decades, human cancer cell line-derived xenografts have been the in vivo models of choice for pre-clinical studies, and with a few notable exceptions, those xenograft models have not been predictive of human clinical efficacy," said Tuan Ha-Ngoc, president and CEO of AVEO Pharmaceuticals. "As a result, clinical development in oncology remains largely empirical, resulting in a greater than 90 percent failure rate and long development timelines with significant capital risk. We believe our HIM model represents the next generation in modeling that will ultimately revolutionize early clinical development."

Murray O. Robinson, PhD, senior vice president of Translational Research at AVEO, added, "One issue with cell line xenografts is that the cell culture conditions for establishing cancer cell lines impart strong selection pressures that are different from those experienced by cells in an in vivo environment. Our proprietary models as part of the Human Response Prediction(TM) Platform provide a defined genetic context as well as an accurate tissue context in which to validat e cancer gene candidates, determine their biological roles in various stages of cancer progression, and test targeted therapies directed against specific genetic lesions found in human breast cancers. We have been very encouraged by the similarity to human patients in both histological appearance and response to agents like Herceptin(R) (trastuzumab)."

AVEO's Proprietary Human Tissue Transgenic HIM Model

AVEO sought to generate an in vivo model of human breast cancer in mice (HIM) by employing a unique tissue recombinant system comprised of human breast stromal cells and epithelial organoids engineered with defined transgenes. Depending on the combination of transgenes employed, the reconstituted human breast tissue developed into preneoplastic lesions (Carcinoma In Situ or CIS) or to invasive adenocarcinomas. Importantly, despite using the same set of genetic alterations, significant variation in tumor phenotype was observed among tumors depending on the source of donor organoids. This last observation suggests that differences in the genetic makeup individual donors may influence the development and progression of these tissue transgenic breast tumors. Because this observed variation is similar to what is seen across human breast cancer patients, AVEO is generating a large number of individual tissue transgenic breast tumors to create a population of tumors in which to explore the relationship between this variation and response to anti-cancer agents.

Ha-Ngoc added, "In addition to capturing variation across a population, the ordered progression observed in this model also provides an opportunity to test drug efficacy in treating early stage tumors. We believe the ability to create genetically manipulated human tumors that develop entirely in an in vivo context may provide a significant advance toward accurately modeling human cancer, which will enable AVEO to guide our clinical development and generate more effective, targeted treatments for cancer."

About AVEO

AVEO is a private biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. The company utilizes its proprietary, genetically-defined cancer models for the identification and validation of novel cancer targets, and has begun to build an impressive portfolio of drug discovery and development programs around these high-value targets. AVEO also uses its Human Response Prediction(TM) Platform to identify genetic profiles that correspond with patient responsiveness. AVEO expects to commence Phase 2 clinical studies by mid-2007 for AV-951, its oral, second-generation VEGF receptor inhibitor and most advanced clinical program. AV-412, AVEO's EGFR/HER2 inhibitor, is currently in Phase I clinical trials. AV-299, a novel anti-HGF mAb, is currently being manufactured by XOMA under a supply agreement in anticipation of entering the clinic in early 2008. AVEO is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.aveopharma.com.

Contact

AVEO Pharmaceuticals, Inc.
JJ Owen, PhD, 617-299-5889
jjowen@aveopharma.com
or
Pure Communications
Adriana Jenkins, 617-744-1713


'"/>




Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... YORK , Feb. 17, 2017   Risperdal ... side effects allegedly associated with use of the atypical ... Philadelphia Court of Common Pleas, where ... mass tort program. According to a notice posted on ... to convene a meeting on March 9, 2017 at ...
(Date:2/17/2017)... 17, 2017 On Thursday, February ... edged lower at the closing bell, while the Dow ... 20,000 benchmark. Moreover, five out of nine sectors ended ... yesterday,s market sentiment, Stock-Callers.com assessed the following Medical Appliances ... (NYSE: SNN ), ABIOMED Inc. (NASDAQ: ...
(Date:2/16/2017)... Inc. (NYSE: DVA ) today announced results for ... Net income attributable to DaVita Inc. for the quarter ... $0.80 per share and $880 million, or $4.29 per share, ... Inc. for the quarter and year ended December 31, 2016, ... $0.98 per share, and $789 million, or $3.85 per share, ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... 2017 , ... Wells Pharmacy Network offers physicians WellsPx3, a ... non-controlled substances plus the ability to manage orders on their desktop or mobile ... electronic prescriptions, according to the Office of the National Coordinator of Health IT, ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... Chief Executive Officer, George Rogers, was named to Staffing Industry Analysts' 2017 "Staffing ... 100 honors those who have made notable contributions to the staffing industry over ...
(Date:2/17/2017)... Plantation, FL (PRWEB) , ... February 17, 2017 ... ... protection services and financial planning assistance to families and business owners in the ... the LifeNet 4 Families organization. , For more than 30 years, LifeNet ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... ... nursing professionalism, teamwork and superiority in patient care, NWH has achieved Magnet® ... on Magnet on Tuesday, January 31, 2017. The American Nurses Credentialing Center’s Magnet ...
Breaking Medicine News(10 mins):